GlycoMimetics (NASDAQ:GLYC) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.26) by 38.46 percent. This is a 52.94 percent increase over losses of $(0.34) per share from the same period last year.
NovaBay Pharmaceuticals Announces Record Ordered Product Sales Of Avenova-Branded Products Through Amazon For April 2024 Increased By More Than 20% Compared With April 2023
Ordered product sales of Avenova®-branded products on Amazon.com set back-to-back records in March and April 2024Enhanced marketing program provides potential for additional growth in the U.S. dry eye disease
